Nyxoah's Genio® System Launches in the Middle East
Nyxoah, a pioneering name in medical technology, has officially launched its Genio® system, a breakthrough therapy aimed at treating Obstructive Sleep Apnea (OSA). This exciting development began with the first successful Genio implant conducted at the renowned Saudi German Hospital, marking a significant advancement in sleep disorder treatments.
First Patient Implantation at Saudi German Hospital
The journey of Genio in the Middle East commenced with a successful implantation by Dr. Ahmed Yassin Bahgat, a leading Consultant Otolaryngologist at the hospital. Celebrating this important milestone, Dr. Bahgat expressed his enthusiasm by stating, "We are proud to be the first hospital in this region to provide Genio to our OSA patients. This innovative therapy is designed for individuals who struggle with traditional CPAP machines."
Importance of Genio® Therapy
Olivier Taelman, CEO of Nyxoah, highlighted the significance of this launch, emphasizing that it represents the first neurostimulation therapy for OSA ever introduced in the area. The Genio device offers a transformative, patient-centered solution, particularly for those who have difficulties with CPAP devices. Taelman noted, "This marks a historic moment in the realm of treatment for obstructive sleep apnea in the Middle East. With robust clinical research backing Genio, we aim to broaden its accessibility and change the lives of patients globally."
About Nyxoah and the Genio® System
Nyxoah is dedicated to redefining the standards of treatment for the one billion people affected by obstructive sleep apnea worldwide. Their flagship product, Genio®, is a groundbreaking device that utilizes hypoglossal neuromodulation. The system is unique as it is battery-free and designed to be implanted through a single incision under the chin, allowing for controlled use via a wearable device. This innovative approach has set new benchmarks in reducing the impact of OSA on patients' lives.
Clinical Evidence and Future Prospects
Following the successful BLAST OSA study, Genio received its CE Mark in 2019, validating its safety and efficacy. Nyxoah has also launched two successful IPOs, first on Euronext Brussels in 2020 and subsequently on NASDAQ in 2021. With recent positive findings from the BETTER SLEEP study, the Genio system now has expanded applications for patients with Complete Concentric Collapse (CCC), a condition previously deemed challenging to treat with existing therapies.
Committed to Innovation
Nyxoah is unwavering in its mission to innovate and enhance treatments for obstructive sleep apnea. The company continues to pursue developments in clinical research, ensuring that Genio remains at the forefront of therapy options available to patients. This commitment reinforces Nyxoah's role as a leader in the field of sleep medicine.
Frequently Asked Questions
What is the Genio® system?
The Genio® system is a neuromodulation device for treating Obstructive Sleep Apnea, offering an innovative alternative to CPAP therapy.
Where was the first Genio implant performed?
The first Genio implant was successfully performed at Saudi German Hospital in Dubai.
What are the benefits of the Genio® therapy?
Genio® therapy provides a patient-friendly solution for OSA, particularly for those intolerant to conventional CPAP machines.
Has the Genio system received any regulatory approval?
Yes, the Genio system received its CE Mark in 2019 and has undergone various clinical studies to ensure its effectiveness.
How does Nyxoah support its innovative solutions?
Nyxoah invests in continuous research and clinical trials to expand the applications of its Genio therapy and enhance patient care.
